表紙
市場調查報告書
商品編碼
1000902

人類乳突病毒微量殼體蛋白質L2 (L2):開發中的藥物,2021年

Human Papillomavirus Minor Capsid Protein L2 (L2) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 33 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

人類乳突病毒微量殼體蛋白質L2 (L2) 非常是微量的殼體成分,沒有形成VLP的能力。這個蛋白質,通過與主要殼體蛋白L1相互作用在殼體穩定中發揮作用。

本報告提供世界各國的人類乳突病毒微量殼體蛋白質L2 (L2) 治療用的開發中產品之開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業的簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
  • 分析範圍
  • 人類乳突病毒微量殼體蛋白質L2 (L2):概要
  • 人類乳突病毒微量殼體蛋白質L2 (L2):治療藥的開發
  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症
  • 各企業開發中的產品
  • 各大學/研究機關開發中的產品
  • 人類乳突病毒微量殼體蛋白質L2 (L2):治療藥的評估
  • 各給藥途徑的評估
  • 各分子類型的評估
  • 人類乳突病毒微量殼體蛋白質L2 (L2):開發治療藥的企業
  • 2A製藥AB
  • Papivax LLC
  • Pathovax LLC
  • 人類乳突病毒微量殼體蛋白質L2 (L2):藥物簡介
  • 2AP-01:藥物簡介
  • 產品概要
  • 作用機制 (MoA)
  • 研究開發 (R&D)的發展情形
  • PVX-01:藥物簡介
  • PVX-2:藥物簡介
  • RGVax:藥物簡介
  • TA-CIN:藥物簡介
  • 人類乳突病毒微量殼體蛋白質L2 (L2):開發暫停的產品
  • 人類乳突病毒微量殼體蛋白質L2 (L2):開發中止的產品
  • 人類乳突病毒微量殼體蛋白質L2 (L2):產品開發里程碑
  • 主要消息和新聞稿
  • 附錄
目錄
Product Code: GMDHC2824TDB

Summary:

Human Papillomavirus Minor Capsid Protein L2 (L2) - L2 is a minor capsid component and lacks the capacity to form VLPs. This protein plays a role in capsid stabilization through interaction with the major capsid protein L1. It also plays a role through its interaction with host dyne in in the intracellular microtubule-dependent transport of viral capsid toward the nucleus. It mediates the viral genome import into the nucleus through binding to host importins.

Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Human Papillomavirus Infections, Cervical Intraepithelial Neoplasia (CIN), Human Papillomavirus (HPV) Associated Cancer and Cervical Cancer.

The latest report Human Papillomavirus Minor Capsid Protein L2 - Drugs in Development, 2021, outlays comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Minor Capsid Protein L2 (L2)
  • The report reviews Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Minor Capsid Protein L2 (L2)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Minor Capsid Protein L2 (L2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Overview
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Assessment
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Companies Involved in Therapeutics Development
  • 2A Pharma AB
  • Papivax LLC
  • Pathovax LLC
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Drug Profiles
  • 2AP-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVX-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVX-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RGVax - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TA-CIN - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Dormant Products
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Discontinued Products
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 25, 2019: 2A Pharma announces the completion of dosing for 2AP01 vaccine
  • Mar 02, 2019: 2A Pharma initiates phase 1 clinical trial of HPV vaccine candidate
  • Dec 14, 2018: 2A Pharma receives approval for phase 1 study of 2AP-01
  • Oct 27, 2016: PathoVax Wins $500,000 in 43North Contest
  • Oct 30, 2014: National Cancer Institute supports next-generation Austrian HPV vaccine
  • Sep 10, 2013: New, Even More Effective HPV Vaccine In Sight
  • Apr 10, 2012: Medigene Presents Preclinical AAVLP Data At World Vaccine Congress
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by 2A Pharma AB, 2021
  • Pipeline by Papivax LLC, 2021
  • Pipeline by Pathovax LLC, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Route of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021